Venture Global’s IPO stumble shows the limits of gassing up a valuation
More generally, markets have a way of recalibrating, and Venture Global’s IPO offers a nuanced lesson. It’s a reminder that valuations aren’t fixed by management or banker decree, but rather hammered out in the back-and-forth with investors.
Metsera, which is developing weight-loss drugs, said on Monday it is seeking a valuation of up to $1.78 billion in its U.S.
Even so the deal solidifies Venture Global’s place in the public markets with an impressive $50 billion market cap. And it ...
HistoSonics Inc., a medical device company whose backers include Johnson & Johnson’s venture capital arm, is weighing a US ...
By Arasu Kannagi Basil (Reuters) -Drug developer Maze Therapeutics said on Monday it was targeting a valuation of up to ...
Maze Therapeutics has set out plans for a $131 million IPO as the company prepares to start dosing its lead kidney drug in a ...
Rexpro Enterprises IPO shows a grey market premium of ₹10, indicating a potential listing price of ₹155. The IPO was ...
The U.S. IPO market is expected to see a blowout 2025, fueled by the return of business-friendly Donald Trump to the White ...
Smithfield Foods could be one of the year's biggest U.S. initial public offerings, with the pork producer planning to raise ...
Steel products maker Colform Group Bhd’s initial public offering (IPO) of 30 million shares has been oversubscribed by 41.82 ...
The U.S. IPO market is moving forward with a steady flow of applicants. Investors this week are awaiting the U.S. Fed's ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback